Blog

Intangible Assets, Earn-Outs in BioPharma Acquisitions

Sorbus Advisors LLC studied purchase price allocations in biopharmaceutical industry titled “Valuation of Goodwill and Intangibles in 2015 BioPharmaceutical Transactions.” The study focused on recognition, valuation, and determination of useful lives of pertinent intangible assets, contingent considerations and goodwill.

While no two acquisitions are the same, common themes in the valuation of intangibles and goodwill can be found along industry lines. Biopharmaceutical companies with the focus on drug development rely on such identifiable intangible assets as developed technology, in-process research and development (in-process R&D), and marketed products. Fair value analysis may be required for less common non-compete agreements and trade names.

Contingent considerations, or earn-outs, often account for a substantial portion of the purchase consideration. It is recorded as a liability. Fair value estimation is performed as of the transaction date and marked to market at the end of each consecutive reporting period. Similarly, in-process R&D has to be valued (or tested for impairment) each reporting period until reclassified into developed product or abandoned.

Relative valuations of goodwill and identifiable intangibles are also consistent within the biopharmaceutical industry. It is common to find a significant portion of excess consideration to be ascribed to goodwill. Marketed products, developed technology and in-process R&D will dependent on the state of therapeutic product pipeline, platform technology and extent of commercial operations.

Download the paper to see the results: HERE.

More Updates

Financial Forecast For Purchase Price Allocation (ASC 805/IFRS 3)

This article covers several key factors to consider when building a financial forecast or projected financial information (PFI).  This guidance is designed for financial forecasts used in purchase price allocations, i.e., valuation of intangible assets as part of purchase accounting under US GAAP ASC 805 and IFRS 3.  Here are a few requirements:   PFI has to be long enough

Shadow Preferred Stock Devalues Convertible Note

Convertible notes are starting to resemble CDOs, collateralized debt obligations that led to the 2008 financial crisis, partly because few understood how they worked. From the economic perspective, convertible notes are complex; that includes Simple  Agreements for Future Equity (SAFEs). In fact, they are referred to as “complex financial instruments” by auditors and financial regulators.  A typical convertible note is

What M&A Purchase Consideration Is Actually Worth?

Most M&A pricing efforts are focused on valuing an acquired business. Essentially no consideration is given to the value of assets an acquirer is giving up in a transaction. We will attempt to clarify some of these issues.

Schedule a Call

Most new projects will require a brief introductory conversation. Unless you are a returning client asking for an update to a old valuation, please use the calendar below to schedule a call with us:

Send a Message

We are located in the San Francisco Bay Area, while our clients cover much broader geography, from Southern California to the East Coast and Europe. Please contact us with questions and inquiries. Also, feel free to stop by on your way to the beautiful Sonoma or Napa Valley.

Schedule a Call